Loading
A phase 2 trial of EMB-01 1600 mg administered once weekly throughout the study in colorectal cancer, run by Shanghai EpimAb Biotherapeutics Co., Ltd., now recruiting.
Phase II Study of EMB-01 in Recurrent/Metastatic Colorectal Cancer Patients is a phase 2 interventional study registered as NCT07314294 by Shanghai EpimAb Biotherapeutics Co., Ltd., with 54 participants planned, started 2025-12-18 and due to reach its primary completion in 2027-12-30. Interventions recorded: EMB-01 1600 mg administered once weekly throughout the study and EMB-01 1600 mg once weekly for 6 weeks, then every 2 weeks thereafter.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Colorectal cancer and the tag pipeline.
Shares Colorectal cancer and the tag pipeline.
Shares Colorectal cancer and the tag pipeline.
Shares Colorectal cancer and the tag pipeline.
Shares Colorectal cancer and the tag pipeline.
Shares Colorectal cancer and the tag pipeline.
Shares Colorectal cancer and the tag pipeline.
Shares Colorectal cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/